These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32946015)

  • 1. ASO Author Reflections: Re-Excision for Ductal Carcinoma In Situ: Who Is at Risk?
    Lamb LR; Bahl M
    Ann Surg Oncol; 2021 Mar; 28(3):1398-1399. PubMed ID: 32946015
    [No Abstract]   [Full Text] [Related]  

  • 2. ASO Author Reflections: Risk of Locoregional Recurrence After Nipple-Sparing Mastectomy and Immediate Breast Reconstruction for Pure Ductal Carcinoma In Situ.
    Wu ZY; Ko B
    Ann Surg Oncol; 2020 May; 27(5):1636-1637. PubMed ID: 32112216
    [No Abstract]   [Full Text] [Related]  

  • 3. ASO Author Reflections: Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ with Suspicion for Microinvasion on Core Needle Biopsy.
    Flanagan MR; Cody HS
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):704. PubMed ID: 31444603
    [No Abstract]   [Full Text] [Related]  

  • 4. ASO Author Reflections: Omitting Radiotherapy for Ductal Carcinoma In Situ Patients with Lumpectomy: Now or in the Future?
    Yang L; Lu D; Bu H
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):891-892. PubMed ID: 32812107
    [No Abstract]   [Full Text] [Related]  

  • 5. ASO Author Reflections: Why Are Young Ductal Carcinoma In Situ Patients Electing to Undergo Bilateral Mastectomies?
    Byun DJ; Gerber NK
    Ann Surg Oncol; 2021 Oct; 28(11):6097-6098. PubMed ID: 33973088
    [No Abstract]   [Full Text] [Related]  

  • 6. ASO Author Reflections: Is Sentinel Lymph Node Biopsy Necessary in Patients with Ductal Carcinoma In Situ with Microinvasion Diagnosed on Core Biopsy?
    Phantana-Angkool A; White RL
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):733-734. PubMed ID: 31916089
    [No Abstract]   [Full Text] [Related]  

  • 7. ASO Author Reflections: Progression after Resection of Noninvasive or Microinvasive Intraductal Papillary Mucinous Neoplasms.
    Al Efishat M; Allen PJ
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):822-823. PubMed ID: 30324467
    [No Abstract]   [Full Text] [Related]  

  • 8. ASO Author Reflections: De-escalation of Surgical Excision for Intraductal Papilloma of the Breast.
    Abbassi-Rahbar S; Amin AL
    Ann Surg Oncol; 2022 Dec; 29(Suppl 3):593-594. PubMed ID: 35211859
    [No Abstract]   [Full Text] [Related]  

  • 9. ASO Author Reflections: Active Surveillance for Ductal Carcinoma In Situ (DCIS).
    Oseni TO; Bahl M
    Ann Surg Oncol; 2020 Oct; 27(11):4466-4467. PubMed ID: 32440718
    [No Abstract]   [Full Text] [Related]  

  • 10. ASO Author Reflections: Improving Identification of Intraductal Papillary Mucinous Neoplasm Patients at Risk-Current Status and the Role of IPMN Molecular Biomarkers.
    Maker AV
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):818-819. PubMed ID: 30311163
    [No Abstract]   [Full Text] [Related]  

  • 11. ASO Author Reflections: Which Patients with Invasive Intraductal Papillary Mucinous Neoplasm Can Benefit from Adjuvant Therapy?
    Croce C; Mungo B; Oba A; Schulick RD; Del Chiaro M
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):873-874. PubMed ID: 32893319
    [No Abstract]   [Full Text] [Related]  

  • 12. ASO Author Reflections: Advising a Woman with Ductal Carcinoma In Situ Regarding Various Treatment Options-A Complex Decision.
    Mamtani A; Van Zee KJ
    Ann Surg Oncol; 2019 Dec; 26(13):4272-4273. PubMed ID: 31549321
    [No Abstract]   [Full Text] [Related]  

  • 13. ASO Author Reflections: Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma.
    Zhang SR; Li H; Wang WQ; Liu L; Yu XJ
    Ann Surg Oncol; 2018 Dec; 25(13):3994-3995. PubMed ID: 30315385
    [No Abstract]   [Full Text] [Related]  

  • 14. ASO Author Reflections: Evolving Paradigms in the Treatment of DCIS: Impact of the SSO-ASTRO Margin Guidelines.
    Mamtani A; Gemignani ML
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):783-784. PubMed ID: 32535869
    [No Abstract]   [Full Text] [Related]  

  • 15. ASO Author Reflections: Tumor-Infiltrating NETs are New Biomarkers to Predict Postsurgical Survival for Patients with Pancreatic Ductal Adenocarcinoma.
    Jin W; Xu HX; Yu XJ; Liu L
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):571-572. PubMed ID: 30710182
    [No Abstract]   [Full Text] [Related]  

  • 16. Endoscopic "string sign".
    Espinel J; Pinedo E; Rascarachi G; Ojeda V
    JOP; 2014 Mar; 15(2):206-7. PubMed ID: 24618448
    [No Abstract]   [Full Text] [Related]  

  • 17. ASO Author Reflections: Health Disparities in Pancreatic Cancer.
    Lutfi W; Hogg ME
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):824-825. PubMed ID: 30377920
    [No Abstract]   [Full Text] [Related]  

  • 18. ASO Author Reflections: Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma.
    Tamburrino D; Guarneri G; Capurso G; Falconi M
    Ann Surg Oncol; 2021 Apr; 28(4):2323-2324. PubMed ID: 32929602
    [No Abstract]   [Full Text] [Related]  

  • 19. ASO Author Reflections: Role of SOX9 Transcription Factor in Pancreatic Neoplasms.
    Turner K; Gnerlich JL
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):567-568. PubMed ID: 30680476
    [No Abstract]   [Full Text] [Related]  

  • 20. ASO Author Reflections: Do Distinct Patterns of Recurrence Impact the Prognosis of Patients With Resected Pancreatic Ductal Adenocarcinoma?
    Groot VP; Wolfgang CL; He J
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):806-807. PubMed ID: 30298312
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.